Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia

Pediatric Blood and Cancer

Volumn 56, Issue 4, 2011, Pages 551-559

  Lund, Bendik ^a,b   Åsberg, Ann ^a   Heyman, Mats ^c   Kanerva, Jukka ^d   Harila Saari, Arja ^e   Hasle, Henrik ^f   Söderhäll, Stefan ^c   Jónsson, Ólafur Gisli ^g   Lydersen, Stian ^h   Schmiegelow, Kjeld ^b,i  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b Rigshospitalet   (Denmark)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF HELSINKI   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^h NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acute lymphoblastic leukaemia; Paediatric oncology; Risk factors; Toxicity; Treatment related death

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE PANCREATITIS; ADOLESCENT; ARTICLE; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CANCER MORTALITY; CANCER RISK; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOWN SYNDROME; DRUG FATALITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION ENCEPHALOPATHY; INFECTION; INTESTINAL BLEEDING; LEUKOCYTE COUNT; LEUKOENCEPHALOPATHY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; TOXIC HEPATITIS; TUMOR VOLUME; VIRUS INFECTION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEMALE; HEMORRHAGE; HUMANS; INFANT; MALE; OPPORTUNISTIC INFECTIONS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; RISK FACTORS; THROMBOSIS; TUMOR BURDEN;

EID: 79551623766     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22719     Document Type: Article

References (43)

1. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000; 14: 2267-2275.
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
3. Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol 2009; 46: 52-63.
4. Prucker C, Attarbaschi A, Peters C, et al. Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: A population-based analysis of the Austrian Berlin-Frankfurt-Munster study group. Leukemia 2009; 23: 1264-1269.
5. Conter V, Arico M, Valsecchi MG, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia 2000; 14: 2196-2204.
6. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-4489.
7. Rubnitz JE, Lensing S, Zhou Y, et al. Death during induction therapy and first remission of acute leukemia in childhood: The St. Jude experience. Cancer 2004; 101: 1677-1684.
8. Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia 2000; 14: 2257-2266.
9. Hargrave DR, Hann II, Richards SM, et al. Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI). Br J Haematol 2001; 112: 293-299.
10. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896-904.
11. Slats AM, Egeler RM, van der Does-van den Berg A, et al. Causes of death-other than progressive leukemia-in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): The Dutch Childhood Oncology Group experience. Leukemia 2005; 19: 537-544.
12. Christensen MS, Heyman M, Mottonen M, et al. Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992-2001. Br J Haematol 2005; 131: 50-58.
13. Wheeler K, Chessells JM, Bailey CC, et al. Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X. Arch Dis Child 1996; 74: 101-107.
14. Kidas E, Moricke A, Beier R, et al. Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: A case-control study. Int J Hematol 2009; 89: 584-591.
15. Davidsen ML, Dalhoff K, Schmiegelow K. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2008; 30: 831-849.
16. Neth O, Hann I, Turner MW, et al. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: A prospective study. Lancet 2001; 358: 614-618.
17. Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 345-354.
18. Schmiegelow K, Al-Modhwahi I, Andersen MK, et al. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study. Blood 2009; 113: 6077-6084.
19. Wollner N, Exelby PR, Lieberman PH. Non-Hodgkin's lymphoma in children: A progress report on the original patients treated with the LSA2-L2 protocol. Cancer 1979; 44: 1990-1999.
20. Hill FG, Richards S, Gibson B, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: Results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 2004; 124: 33-46.
21. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol 2001; 19: 697-704.
22. Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review. J Clin Oncol 2008; 26: 2767-2778.
23. Pui CH. Childhood leukemias. New York: Cambridge University Press; 2006.
24. Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 1997; 99: 580-588.
25. Eyrich M, Wiegering V, Lim A, et al. Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia-A prospective study of 20 paediatric patients. Br J Haematol 2009; 147: 360-370.
26. Conter V, Arico M, Valsecchi MG, et al. Intensive BFM chemotherapy for childhood ALL: Interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. Haematologica 1998; 83: 791-799.
27. Phillips B, Selwood K, Lane SM, et al. Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centres. Arch Dis Child 2007; 92: 495-498.
28. Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87: 540-546.
29. Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49: 1306-1311.
30. Goorin AM, Hershey BJ, Levin MJ, et al. Use of trimethoprim-sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatr Infect Dis 1985; 4: 265-269.
31. Hughes WT, Rivera GK, Schell MJ, et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987; 316: 1627-1632.
32. Schroder H, Agger KE, Rosthoj S, et al. Antibacterial prophylaxis with trimethoprim-sulfamethoxazole during induction treatment for acute lymphoblastic leukemia. Dan Med Bull 2001; 48: 275-277.
33. van de Wetering MD, de Witte MA, Kremer LC, et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: A systematic review of randomised controlled trials. Eur J Cancer 2005; 41: 1372-1382.
34. Takahashi N, Kameoka Y, Yamanaka Y, et al. Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma. Intern Med 2008; 47: 651-653.
35. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance. Clin Pharmacokinet 2000; 38: 111-180.
36. Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: How do we prevent and treat them? Clin Infect Dis 2010; 50: 405-415.
37. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
38. Lehrnbecher T, Bernig T, Hanisch M, et al. Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 2005; 19: 1745-1750.
39. Middleton PG, Cullup H, Dickinson AM, et al. Vitamin D receptor gene polymorphism associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic bone marrow transplantation. Bone Marrow Transplant 2002; 30: 223-228.
40. Shamim Z, Ryder LP, Heilmann C, et al. Genetic polymorphisms in the genes encoding human interleukin-7 receptor-alpha: Prognostic significance in allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37: 485-491.
41. Kearney SL, Dahlberg SE, Levy DE, et al. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer 2009; 53: 162-167.
42. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003; 97: 508-516.
43. Biondi A, Baruchel A, Hunger S, et al. The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, 6-7 May 2009. Leukemia 2009.